I-Corps: Photodynamic Cancer Therapy Innovation
I-Corps: Photodynamic Cancer Therapy Innovation
批准号:
1542256
负责人:
Matthew Gdovin
金额:
$5.0万
依托单位国家:
美国
项目类别:
Standard Grant
财政年份:
2015
资助国家:
美国
项目状态:
已结题
起止时间:
2015-06-01 至 2016-05-31
中文摘要
三阴性乳腺癌(TNBC)是最具侵袭性、致命性的乳腺癌之一,由于缺乏雌激素、孕激素和人表皮生长因子(HER-2)受体,许多现有的药物治疗对患者的生存影响有限。拟议的创新旨在解决缺乏有效治疗TNBC的靶向疗法的问题,因为缺乏有效的靶向方法是诊断为TNBC的患者的一个重大障碍。由于TNBC对化疗的反应很差,因此经常进行乳房切除术以提高总存活率。这项拟议的创新可能会消除切除乳房的需要。潜在客户包括医生、医疗保健管理人员和患者。除了将为我们的治疗开处方的肿瘤学家外,客户还将包括影响使用拟议治疗的决定的人。这些客户将包括医疗保健提供者。通过光去质子诱导细胞内酸中毒一直没有被作为一种对细胞造成损害的技术来研究。释放大量的氢离子会对生物系统造成不同程度的破坏,并可用于导致局部区域(如肿瘤内)的细胞凋亡。这种对细胞内pH的根本改变几乎不可能获得抵抗力,已被证明在体外和体内导致显著的癌细胞死亡方面非常有效,具有尖锐的焦点效应,利用最近开发的pH诱导光动力学纳米颗粒为特定细胞靶向提供无限潜力,并且是一种丰富且相对便宜的化合物。这种知识产权的商业可行性具有巨大的潜力,因为在体外和体内导致TNBC细胞显著死亡的作用机制并不是癌症特有的。如果开发并进入市场,建议的细胞内酸中毒抗癌技术有可能与目前的化疗、放射或手术治疗癌症的方法相媲美或超过。这个i-Corps团队打算确定TNBC治疗领域所有负责人目前未得到满足的需求,特别是肿瘤学家、医院管理人员、制药公司、患者和FDA监管机构。该团队还将确定药代动力学和药效学研究的需求。在项目结束时,该团队将起草一份商业计划,其中将包括使命声明、目标、成功的关键、产品和服务、管理计划、包括客户在内的市场分析、定价、竞争和交付,以及可衡量的进展里程碑。
英文摘要
Triple Negative Breast Cancer (TNBC) represents one of the most aggressive, deadly forms of breast cancer, and because this cancer lacks estrogen, progesterone, and Human Epidermal Growth Factor (HER-2) receptors, many existing pharmacological treatments have a limited effect on patient survival. The proposed innovation aims to address the lack of targeted therapies for effective treatment of TNBC, as the lack of an efficient targeted approach represents a significant barrier for patients diagnosed with TNBC. Because TNBC responds so poorly to chemotherapy, a mastectomy is often performed to increase overall survival. The proposed innovation may eliminate the need for mastectomy. Potential customers include physicians, health care administrators, and patients. In addition to oncologists that would prescribe our treatment, customers would also include people who influence the decision to use the proposed treatment. These customers would include health care providers.Induction of intracellular acidosis via photo uncaging of protons has until not been pursued as a technique for inflicting damage to cells. Releasing significant concentrations of hydrogen ions causes variable disruption to biological systems, and can be used to cause apoptotic cell death in a focal region such as within a tumor. This fundamental alteration to cells intracellular pH is almost impossible to garner a resistance toward, has been shown to be highly effective in causing significant cancer cell death in vitro and in vivo, has an acutely focal effect providing limitless potential for specific cell targeting using a recently developed pH-inducing photodynamic nanoparticle, and is an abundant and relatively inexpensive chemical compound. The commercial viability of this intellectual property has tremendous potential, as the mechanisms of action employed in causing significant death of TNBC cells in vitro and in vivo is not cancer specific. If developed and entered into the market, the proposed intracellular acidosis anti-cancer technique has the potential to rival or surpass current chemotherapeutic, radiation, or surgical methods of cancer treatment. This I-Corps team intends to establish the current unmet needs of all principals in the TNBC treatment space, specifically oncologists, hospital administrators, pharmaceutical companies, patients, and FDA regulators. The team will also identify needs for pharmacokinetic and pharmacodynamics studies. At the end of the project this team will draft a business plan which will include a mission statement, objectives, keys to success, products and services, management plan, market analysis to include customers, pricing, competition, and delivery, and measurable milestones of progress.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
SBIR Phase I: An energy-based therapeutic to treat prostate cancer
-
批准号:2013897
-
项目类别:Standard Grant
-
资助金额:$22.5万
-
财政年份:2020
-
负责人:Matthew Gdovin
-
依托单位:
海外基金